EU Clears Celgene's Abraxane To Treat Pancreatic Cancer

Law360, New York (January 7, 2014, 5:48 PM EST) -- Drugmaker Celgene Corp. said Tuesday that European regulators have greenlighted a mixture involving its drug Abraxane as a new treatment for pancreatic cancer.

The European Commission approved a combination of Abraxane and gemcitabine to treat pancreatic cancer that has spread to other parts of the body. The U.S. Food and Drug Administration approved Abraxane, a drug that has previously been used to treat breast cancer, for a similar use to treat pancreatic cancer in September. Celgene said it will release the drug in the European Union...
To view the full article, register now.